Texas AG accuses Janssen of fraud
Pharma Compliance Alert, December 24, 2008
The Texas attorney general alleges Janssen Pharmaceutica used kickbacks and false marketing to defraud the state’s Medicaid agency, according to a new filing.
According to the filing, Janssen paid kickbacks and distributed false marketing materials for its schizophrenia drug, Risperdal, to get the drug on Texas’ list of preferred Medicaid drugs. The state claims the company paid third-party contractors and nonprofit groups to promote Risperdal and create the impression the drug was widely supported. In addition, Janssen allegedly compromised the objectivity of scientists performing research by providing them with funding, consulting fees, extravagant meals and travel.
A Janssen spokesperson said the allegations have no merit and the company only promotes products for FDA-approved uses, according to a Dallas Morning News article.
Comments
0 comments on “Texas AG accuses Janssen of fraud ”
Related Products
-
ePharm5 InDepth
EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...
-
Healthcare Marketing Advisor
Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...
-
Stark Law, 2nd edition: A user's guide to achieving compliance
This updated version of HCPro's Stark Law best seller, first published in 2005—and now co-authored by former CMS Stark...
-
Emergency Management Coordinator's Handbook for Hospitals
This book and CD-ROM is an affordable, easy-to-read reference that outlines the fundamental processes of emergency...
-
Marketing Oncology: Strategies for Service Line Campaigns
During this 90-minute Webcast, expert healthcare marketers discuss the research and strategic planning that should be the...
Most Popular
- Articles
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- Topic: CMS, OESS post new security compliance review information, checklist
- What does case-mix index mean to you?
- QA:Coding multiple initial infusions
- Capturing all necessary codes for IUD insertion and removal can be challenging
- News and briefs: Oklahoma Osteopathic Association against residency bill change
- OB services: Coding inside and outside of the package
- HIPAA Q&A: Level of encryption needed for email
- E-mailed
-
- Q/A: Volume requirement for reporting hydration services
- Featured blog post: Nurses face felony charges after reporting physician to the Texas Medical Board
- Catch up on what's new with injections and infusions
- New conflicts of interest create new challenges
- Joint Commission Center announces handoff communication solutions
- Inside best practice: Reduce patient falls with a stoplight
- Identify modifiable risk factors to prevent patient falls
- Hospitalist-surgeon comanagement has no effect on outcomes
- HIPAA Q&A: Level of encryption needed for email
- Case Management Monthly, June 2012
- Searched